- Understand the mechanisms by which advanced prostate and other immune-refractory cancers evade anti-tumor immunity
- Elucidate therapeutic strategies to enhance innate immunity within the tumor microenvironment, thereby overcoming resistance to immunotherapy.
- Discuss the development of immuno-oncology combination clinical trials in molecularly-defined subsets of advanced prostate and endometrial cancers.
08/26/2019 - 12:00pm to 1:00pm CDT
900 East 57th StreetKCBD Auditorium 1103
Chicago, IL 60637
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Akash Patnaik, MD, PhD, MMSc